We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sun Pharma got a start in Japan when it paid Novartis nearly $300 million a couple of years ago for more than a dozen drugs the Swiss drugmaker was unloading.
A Chinese maker of heparin, APIs and some finished drugs is launching the second phase of its manufacturing plant, investing nearly $150 million as it moves into producing innovative biologic drugs for the Chinese market.
Just months after announcing a $65 million expansion that will boost capacity at the North Carolina facility where it makes diabetes medications, Novo Nordisk says it needs yet more...